Announcement for the Infectious Diseases, Vaccines, and Immunity Frontier Symposium: Dr. WenQing Yang, Our Co-Founder/CSO, to Attend WCID2024 and Deliver Keynote Address
2024-10-23
The 7th World Congress on Infectious Diseases (WCID 2024) and the 4th International Vaccine Congress will take place from October 24 to 26, 2024, in Baltimore, Maryland, USA. The conference will bring together scientists, healthcare professionals, researchers, and policymakers from around the world to discuss key issues in infectious diseases, vaccine development, and immunological disorders. The theme is "Global Challenges, Unified Solutions: Advancing Infectious Disease and Vaccine Research and Response," aiming to address the global challenges posed by infectious diseases.
WCID General Assembly topics
Dr. WenQing Yang, Co-Founder and Chief Scientific Officer of ClinBridge Biotech, will participate as a member of the WCID 2024 Scientific Committee and deliver a keynote titled: "Fueling Innovative Drug Research/Development Process with Patient-Centric and Clinically Relevant Translational Models." Dr. Yang will highlight the breakthroughs and challenges in innovative drug development and discuss how leveraging patient-centric, clinically relevant translational tools can significantly enhance the success rate of drug development.
Partial Agenda for the Plenary Speech Session of the WCID 2024
Dr. Yang is a distinguished translational scientist with over 30 years of experience, specializing in oncology and autoimmune diseases. He has published over 100 papers and contributed to more than 30 innovative drug applications. His expertise and leadership in the field are recognized globally, making him a frequent guest speaker and committee member at international conferences.
ClinBridge Biotech focuses on developing clinically relevant preclinical models for multi-disciplinary areas including infectious diseases, vaccines, and autoimmune disorders to support innovative drug research, aiming to improve patient outcomes. Dr. Yang's participation at WCID 2024 reinforces the company’s commitment to its mission of serving patients through cutting-edge translational research.
ClinBridge Biotech Co. Ltd is a platform-focused company specializing in preclinical evaluation for innovative drugs and medical devices. The company's core mission is to enhance the clinical translation rate of new drugs through the use of highly clinically relevant disease animal models. ClinBridge is dedicated to establishing tumor pharmacology, tumor immunology, and autoimmune disease models, as well as drug evaluation systems closely linked to patients' pathological microenvironments, aiming to address the challenges of preclinical translation in the industry. The company boasts AAALAC-accredited SPF-level small and large animal experimental centers, along with well-equipped molecular biology, in vitro pharmacology, biomarker, bioanalysis, and animal imaging laboratories. ClinBridge offers end-to-end preclinical services, including drug screening, pharmacology, DMPK, and safety evaluations. With an innovative translational approach, a differentiated core platform, evolving disease animal models, multimodal imaging technologies, and solid technical expertise, ClinBridge is committed to providing comprehensive preclinical solutions to help both domestic and international companies and research institutions bring innovative drugs and medical devices to clinical application.
联科
Official Public Number
Copyright©2023 Nanjing Yunqiao Purui Biotechnology Co., Ltd.
